TESARO (TSRO) : The total money flow in TESARO (TSRO) was negative ($2.72 million), which signals selling by the traders on Wednesdays session. They trimmed their holdings by selling the stock on downticks to the tune of $11.12 million. In comparison, the inflow of money into the stock on upticks was $8.4 million. The uptick to downtick ratio was 0.76. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $3.96 million. The value of transactions on uptick was $1.65 million. The negative money flow of ($2.31 million) confirms the selling in TESARO (TSRO) on strength. The uptick to downtick ratio of block trades was 0.42. TESARO (TSRO) gained $2.62 at $91.91, a gain of 2.93% over the previous days close. However, the stock registered 4.38% in the week.
Also, Brokerage firm Jefferies downgrades its rating on TESARO (NASDAQ:TSRO). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on June 30, 2016.
TESARO (NASDAQ:TSRO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $89.56 and $89.40 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $92.48. The buying momentum continued till the end and the stock did not give up its gains. It closed at $92.33, notching a gain of 3.40% for the day. The total traded volume was 677,657 . The stock had closed at $89.29 on the previous day.
The stock has recorded a 20-day Moving Average of 26.51% and the 50-Day Moving Average is 66.87%. In a related news,The Officer (Executive Vp, R&D And Cso) of TESARO, Inc., Hanke Jeffrey H. sold 12,500 shares at $74.02 on June 30, 2016. The Insider selling transaction had a total value worth of $925,250. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.